Pharmaceuticals, Biotechnology and Life Sciences
CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard…
CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard…
CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard…
CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard…
CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard…
NEW HAVEN, Conn.–(BUSINESS WIRE)–#Rallybio–Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with…
NEW HAVEN, Conn.–(BUSINESS WIRE)–#Rallybio–Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with…
NEW HAVEN, Conn.–(BUSINESS WIRE)–#Rallybio–Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with…
NEW HAVEN, Conn.–(BUSINESS WIRE)–#Rallybio–Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with…
NEW HAVEN, Conn.–(BUSINESS WIRE)–#Rallybio–Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with…